Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update
- PMID: 38793067
- PMCID: PMC11122522
- DOI: 10.3390/jpm14050483
Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update
Abstract
Severe cancer pain substantially affects patients' quality of life, increasing the burden of the disease and reducing the disability-adjusted life years. Although opioid analgesics are effective, they may induce opioid-induced bowel dysfunction (OIBD). Oxycodone/naloxone combination therapy has emerged as a promising approach to mitigate opioid-induced constipation (OIC) while providing effective pain relief. This review provides an updated analysis of the literature of the last decade regarding the use of oxycodone/naloxone in the management of severe cancer pain. Through a comprehensive search of databases, studies focusing on the efficacy, safety, and patient experience of oxycodone/naloxone's prolonged release in severe cancer pain management were identified. Furthermore, the literature discusses the mechanism of action of naloxone in mitigating OIC without compromising opioid analgesia. Overall, the evidence suggests that oxycodone/naloxone combination therapy offers a valuable option for effectively managing severe cancer pain while minimizing opioid-induced constipation, thereby improving patients' quality of life. However, further research is needed to optimize dosing regimens, evaluate long-term safety, and assess patient outcomes in diverse cancer populations.
Keywords: oxycodone/naloxone 2; pain management 3; severe cancer pain 1.
Conflict of interest statement
Author 3 (M.P.) is an employee of company “Contenuto Ed Net Communications SL”. The company had no role in the design, execution, interpretation, or writing of the study.
Figures
References
-
- Sizar O., Genova R., Gupta M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Opioid-Induced Constipation. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
